LQDA

Company Overview — What Does Liquidia Corp Do?

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. Liquidia Corp (LQDA) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Roger A. Jeffs and employs approximately 50 people. With a market capitalization of $3.3B, LQDA is one of the notable companies in the Healthcare sector.

Liquidia Corp (LQDA) Stock Rating — Hold (April 2026)

As of April 2026, Liquidia Corp receives a Hold rating with a composite score of 38.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.LQDA ranks #1,975 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Liquidia Corp ranks #209 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LQDA Stock Price and 52-Week Range

Liquidia Corp (LQDA) currently trades at $38.00. The stock lost $2.32 (5.8%) in the most recent trading session. The 52-week high for LQDA is $46.67, which means the stock is currently trading -18.6% from its annual peak. The 52-week low is $11.26, putting the stock 237.5% above its annual trough. Recent trading volume was 1.4M shares, reflecting moderate market activity.

Is LQDA Overvalued or Undervalued? — Valuation Analysis

Liquidia Corp (LQDA) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 73.57x, versus the sector average of 2.75x. The price-to-sales ratio is 46.53x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, LQDA trades at 405.73x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Liquidia Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Liquidia Corp Profitability — ROE, Margins, and Quality Score

Liquidia Corp (LQDA) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -238.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.5% versus the sector average of -33.1%.

On a margin basis, Liquidia Corp reports gross margins of 58.1%, compared to 71.5% for the sector. The operating margin is -553.2% (sector: -66.1%). Net profit margin stands at -556.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1385.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LQDA Debt, Balance Sheet, and Financial Health

Liquidia Corp has a debt-to-equity ratio of 633.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.01x, indicating strong short-term liquidity. Total debt on the balance sheet is $192M. Cash and equivalents stand at $157M.

LQDA has a beta of 1.06, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Liquidia Corp is 41/100, reflecting average volatility within the normal range for its sector.

Liquidia Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Liquidia Corp reported revenue of $71M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-107M. Gross margin was 58.1%. Operating income came in at $-100M.

In FY 2025, Liquidia Corp reported revenue of $158M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-69M. Revenue grew 1031.2% year-over-year compared to FY 2024. Operating income came in at $-51M.

In Q3 2025, Liquidia Corp reported revenue of $54M and earnings per share (EPS) of $-0.04. Net income for the quarter was $-4M. Revenue grew 1121.7% year-over-year compared to Q3 2024. Operating income came in at $2M.

In Q2 2025, Liquidia Corp reported revenue of $9M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-42M. Revenue grew 141.5% year-over-year compared to Q2 2024. Operating income came in at $-38M.

Over the past 8 quarters, Liquidia Corp has demonstrated a growth trajectory, with revenue expanding from $4M to $71M. Investors analyzing LQDA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LQDA Dividend Yield and Income Analysis

Liquidia Corp (LQDA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LQDA Momentum and Technical Analysis Profile

Liquidia Corp (LQDA) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

LQDA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Liquidia Corp (LQDA) ranks #209 out of 838 stocks based on the Blank Capital composite score. This places LQDA in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LQDA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LQDA vs S&P 500 (SPY) comparison to assess how Liquidia Corp stacks up against the broader market across all factor dimensions.

LQDA Next Earnings Date

No upcoming earnings date has been announced for Liquidia Corp (LQDA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LQDA? — Investment Thesis Summary

Liquidia Corp presents a balanced picture with arguments on both sides. The quality score of 15/100 flags below-average profitability. The value score of 33/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers.

In summary, Liquidia Corp (LQDA) earns a Hold rating with a composite score of 38.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LQDA stock.

Related Resources for LQDA Investors

Explore more research and tools: LQDA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LQDA head-to-head with peers: LQDA vs AZN, LQDA vs SLGL, LQDA vs VMD.